Chemotherapy Combination Boosts Overall Survival in Patients with EGFR-mutant Non-Small Cell Lung Cancer
October 17, 2025
October 17, 2025
BOSTON, Massachusetts, Oct. 17 [Category: BizHospital] -- The Dana-Farber Cancer Institute issued the following news release:
* * *
Chemotherapy Combination Boosts Overall Survival in Patients with EGFR-mutant Non-Small Cell Lung Cancer
*
Final analysis of Dana-Farber co-led phase 3 FLAURA2 study underscore benefits of adding chemotherapy to existing standard first line therapy with an EGFR-TKI.
Treatment with osimertinib plus a p . . .
* * *
Chemotherapy Combination Boosts Overall Survival in Patients with EGFR-mutant Non-Small Cell Lung Cancer
*
Final analysis of Dana-Farber co-led phase 3 FLAURA2 study underscore benefits of adding chemotherapy to existing standard first line therapy with an EGFR-TKI.
Treatment with osimertinib plus a p . . .